


LEGEND-T2DM Evidence Dissemination Summary

Target: **sitagliptin**, Comparator: **empagliflozin** Outcome: **Venous thromboembolic events** Subgroup: **All**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	41,406	34,273	169	4.93
Clinformatics	13,325	9,695	87	8.97
DA Germany	14,979	15,278	126	8.25
LDP France	-	-	-	-
MDCD	6,375	4,371	42	9.61
MDCR	6,131	4,747	47	9.90
Open Claims	561,992	493,786	2,381	4.82
Optum EHR	52,007	24,938	201	8.06
Veterans Affairs	238	171	<10	<58.39

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

